ENTITY
Shanghai Henlius Biotech

Shanghai Henlius Biotech (2696 HK)

103
Analysis
Health CareChina
Shanghai Henlius Biotech, Inc develops and produces drugs. The Company develops and produces monoclonal antibody biosimilar drugs, bio betters, novel monoclonal antibodys, and other drugs. Shanghai Henlius Biotech throughout China.
more
Refresh
24 Oct 2020 23:47

What HKEX Biotech "Step-Ups" Can Tell Us

This Insight explains the concept of valuation "step-ups" for pre-revenue biotechnology companies listing on the HKEX and how to use this data to...

Share
19 Oct 2020 16:46

China Healthcare Weekly (Oct.16)

This article summarized major industry viewpoints, company news, and capital market review for China healthcare industry last week.

Logo
241 Views
Share
13 Oct 2020 09:53

China Healthcare Weekly (Oct.9)

This insight summarized the important industry viewpoints, news of listed healthcare companies and capital market review for the last week of China...

Logo
226 Views
Share
17 Sep 2020 01:38

JHBP Holdings (Genor Biopharma) IPO Initiation: Hunting for a Cure

$ Genor Biopharma is a biopharmaceutical company focusing on developing and commercializing oncology and autoimmune drugs. Its drug candidates...

Logo
442 Views
Share
18 Mar 2020 12:02

Trade Idea: Short Henlius Upon Lock-Up Expiry & 2H Results, HLX01 Likely Underperformed

Shanghai Henlius Biotech (2696 HK) IPO lock-up will expire on 25th of March, six months post its listing. The stock has been underwater since...

Logo
346 Views
Share
x